Blood pressure drug prazosin tested against diabetes risk in PTSD

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Veteran of the US military 2. Diagnosis of post-traumatic stress disorder (PTSD) defined by Diagnostic and Statistical Manual of Mental Disorders (DSM-5) symptom count on Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Exclusion Criteria: 1. Any form of diabetes as defined by the American Diabetes Association. Exceptions may be made for participants with previously undiagnosed, early, asymptomatic Type 2 Diabetes Mellitus (T2DM) who meet American Diabetes Association criteria for diabetes during study screening who wish to be included 2. Diagnosis of DSM-5-defined bipolar I, schizophrenia spectrum or other psychotic disorders (by MINI) 3. Diagnosis of dementia or related progressive neurocognitive disorder, based on clinical records 4. Diagnosis of moderate or severe substance use disorder (except for caffeine and nicotine) during the preceding 3 months 5. Current use or use within the past 2 weeks of a medication with significant 1-AR or 2-AR activity (prazosin, doxazosin, alfuzosin, clonidine, guanfacine), or opiates 6. Current use or use within the past 3 months of antipsychotics, glucocorticoid medications, or glucose-lowering medications, including but not limited to metformin and GLP-1 agonists 7. Contraindication to prazosin 8. History of moderate or severe Traumatic Brain Injury (TBI) as defined by the Ohio State University TBI Identification Method 9. Increased risk of suicide that necessitates inpatient treatment, intensive outpatient care, or treatment excluded by the protocol 10. Pregnancy or lactation, or anticipated pregnancy at any point during study participation 11. Ongoing or initiation of new treatment with evidence-based trauma-focused therapy for post-traumatic stress disorder (PTSD) within 2 weeks of baseline. Supportive psychotherapy may be continued during the study. 12. Current enrollment in another interventional trial for post-traumatic stress disorder (PTSD)